Vivos Therapeutics (VVOS) versus Its Peers Financial Analysis

Vivos Therapeutics (NASDAQ:VVOS) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Vivos Therapeutics to similar businesses based on the strength of its institutional ownership, risk, profitability, dividends, analyst recommendations, valuation and earnings.

Institutional and Insider Ownership

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Vivos Therapeutics has a beta of 6.37, indicating that its share price is 537% more volatile than the S&P 500. Comparatively, Vivos Therapeutics’ competitors have a beta of 2.57, indicating that their average share price is 157% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vivos Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	1	2	0	2.25
Vivos Therapeutics Competitors	4264	10506	18254	825	2.46

Vivos Therapeutics currently has a consensus target price of $2.80, indicating a potential upside of 2,417.99%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 17.36%. Given Vivos Therapeutics’ higher probable upside, research analysts clearly believe Vivos Therapeutics is more favorable than its competitors.

Profitability

This table compares Vivos Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
Vivos Therapeutics Competitors	-278.16%	-150.10%	-21.89%

Earnings & Valuation

This table compares Vivos Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vivos Therapeutics	$17.44 million	-$21.17 million	-0.06
Vivos Therapeutics Competitors	$1.88 billion	$138.21 million	11.30

Vivos Therapeutics’ competitors have higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Vivos Therapeutics competitors beat Vivos Therapeutics on 10 of the 13 factors compared.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.